Patients with coronary heart disease and angina pectoris, patients with heart blood stasis based on TCM differentiation
Conditions
Interventions
Experimental group:According to the requirements of ACC/AHA coronary heart disease angina pectoris diagnosis and treatment guidelines, he received antiplatelet therapy, statins and nitrates. Rhodiola
Control group:According to the ACC/AHA coronary heart disease angina pectoris diagnosis and treatment guidelines, he received antiplatelet therapy, statins and nitrates.
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with coronary heart disease and angina pectoris diagnosis; 2. Patients who are currently receiving standard treatment for coronary heart disease and angina pectoris; 3. The age is from 18 to 75 years old; 4. Patients with heart blood stasis syndrome differentiation; 5. Patients who voluntarily accept the drug and sign informed consent. The informed consent process is in accordance with the relevant provisions of GCP.
Exclusion criteria
Exclusion criteria: 1. Patients with grade IV cardiac function (see Annex 4: NYHA classification); or patients with high risk of angina pectoris; 2. Patients with uncontrolled grade III hypertension (systolic blood pressure >=180mmhg and / or diastolic blood pressure >=110mmhg), severe cardiopulmonary dysfunction, serious arrhythmia, serious primary diseases of liver, kidney and hematopoietic system, or patients with serious diseases (such as tumors) and mental patients that affect their survival. 3. Patients with a history of hemorrhagic disease or other hemorrhagic diseases (PLT < 100x10^9/L); 4. Patients with abnormal liver and renal function indexes (alt, AST, SCR exceeding the upper limit of normal reference range by 2 times); 5. Aspirin contraindication patients; 6. Allergic constitution, or those who are allergic to various drugs and foods, or patients who are known to be allergic to the research drug (including its ingredients); 7. Pregnant or preparing for pregnancy and lactation; 8. Patients who participated in other clinical studies in the past month; 9. Patients considered unsuitable for clinical trials by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of major adverse cardiovascular events (major adverse cardiovascular events include cardiovascular death, non-fatal myocardial infarction, and revascularization); | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome curative effect;Angina pectoris efficacy; | — |
Countries
China
Contacts
Public ContactYang Zhongqi
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed